Overview

This two part programme will consider our current guideline-directed approach to chronic kidney disease (CKD) and how SGLT-2 inhibitors can be used to maximal effect. Join us for part one on 11 March for a unique case-based discussion, chaired by Prof James Burton (University of Leicester, UK) with expert insight from a world-renowned faculty, Prof David Wheeler (University College London, UK), Dr Navdeep Tangri (University of Manitoba, CA), and Prof Carol Pollock (University of Sydney, AUS).

In this dynamic series, our expert panel will unravel the complexities of CKD care in the context of a real-world patient case. Part two, on 18 April, will offer a forensic analysis of current practices, revisiting the patient case in reflection of expected guideline updates. In this part, our panel will provide you with evidence-based strategies for initiating pharmacological therapies that transcend the theoretical and become actionable in everyday practice.

Elevate your understanding, challenge clinical norms, and be at the forefront of CKD care. Mark your calendar for these pivotal sessions and be part of the movement shaping the future of kidney health.

This CME programme* is supported by an unrestricted educational grant from AstraZeneca. 

*An Expert Approach to Cardio-Renal Protection in CKD’s programme has been submitted to the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) seeking 2 CME points, equating to 2 hours of learning.

Part 1 starts in:

Part 2 starts in:

Share this event:

Faculty

James Burton

James Burton
Chair
University of Leicester, UK

more info

Carol Pollock

Carol Pollock

University of Sydney, AUS

more info

Navdeep Tangri

Navdeep Tangri

Max Rady College of Medicine, Manitoba, CA

more info

David Wheeler

David Wheeler

University College London, UK

more info

Learning Objectives

  • Recall clinical evidence and guidelines for the management of CKD patients without diabetes
  • Describe current gaps and barriers in evidence-based management for CKD without diabetes
  • Apply evidence based-management strategies to a case study
  • Use expert-led guidance to develop an optimal management approach to CKD patients without diabetes

Target Audience

  • Cardiologists
  • Heart Failure Specialists
  • Nephrologists
  • Primary Care Physicians

Kidney Disease: Improving Global Outcomes (KDIGO) group

KDIGO is a global organisation developing and implementing evidence-based clinical practice guidelines in kidney disease. It is an independent, volunteer-led, self-managed foundation incorporated in Belgium and accountable to the public and the patients it serves.

KDIGO has a network of dedicated volunteers from around the world who promote awareness, dissemination, adoption, and clinical integration of KDIGO Guidelines both globally and in their respective countries or regions.

KDIGO guidelines translate scientific advances into useful and practical clinical practice recommendations and observations.

About Radcliffe Medical Education

We are Radcliffe, a knowledge network for the cardiovascular community

We’re here to bring cardiovascular knowledge, insight and innovation to life for clinicians around the world, using our communications and creative expertise, our platforms and connections across the community to help transform theory into practice faster and more effectively.

We bring medical knowledge to life

From great science writing and smart journal editing, the curation of evidence based and peer-reviewed content, to engaging new formats that cut through the noise, we believe that communication is at the heart of great healthcare.

Our work is underpinned by 3 core principles:

  • We build on the best science
  • We work hands-on with our community
  • We bring fresh thinking


Our promise is that we’ll equip you with the latest knowledge and skills you need, to do the best for your patients.

For more information on Radcliffe Medical Education, please visit www.radcliffemedicaleducation.org